Lilly Doubles Down on Insomnia with Hypnion Acquisition
This article was originally published in Start Up
Executive Summary
Eli Lilly added its second insomnia program with the acquisition of privately held Hypnion Inc. Hypnion's Phase II HY10275 compound is the industry's most advanced dual H1/5HT2a antagonist in clinical development. Hypnion management told START-UP that M&A was its preferred exit, given the resources necessary to develop HY10275 to its full potential.